Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges (2022)
- Authors:
- USP affiliated authors: HALLAK, JAIME EDUARDO CECILIO - FMRP ; SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; ROSSI, GIORDANO NOVAK - FMRP
- Unidade: FMRP
- DOI: 10.1080/14740338.2022.2066650
- Subjects: ANTIDEPRESSIVOS; FÁRMACOS PSICOTRÓPICOS; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
- Keywords: Psilocybin; Adverse events; Depression; Rapid acting antidepressants; Psychedelics
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Expert Opinion on Drug Safety
- ISSN: 1474-0338
- Volume/Número/Paginação/Ano: v. 21, n. 6, p. 761-776, 2022
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
ROSSI, Giordano Novak et al. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, v. 21, n. 6, p. 761-776, 2022Tradução . . Disponível em: https://doi.org/10.1080/14740338.2022.2066650. Acesso em: 29 maio 2024. -
APA
Rossi, G. N., Hallak, J. E. C., Saiz, J. C. B., & Santos, R. G. dos. (2022). Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, 21( 6), 761-776. doi:10.1080/14740338.2022.2066650 -
NLM
Rossi GN, Hallak JEC, Saiz JCB, Santos RG dos. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges [Internet]. Expert Opinion on Drug Safety. 2022 ; 21( 6): 761-776.[citado 2024 maio 29 ] Available from: https://doi.org/10.1080/14740338.2022.2066650 -
Vancouver
Rossi GN, Hallak JEC, Saiz JCB, Santos RG dos. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges [Internet]. Expert Opinion on Drug Safety. 2022 ; 21( 6): 761-776.[citado 2024 maio 29 ] Available from: https://doi.org/10.1080/14740338.2022.2066650 - The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
- Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts
- Molecular pathways of the therapeutic effects of Ayahuasca, a botanical psychedelic and potential rapid-acting antidepressant
- Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms
- Adverse effects after Ayahuasca administration in the clinical setting [Carta]
- Polypharmacology or “pharmacological promiscuity” in psychedelic research: what are we missing?
- Natural hallucinogens in mental health [Editorial]
- Effects of ayahuasca on mental health and quality of life in naïve users: a longitudinal and cross-sectional study combination
- Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual Ayahuasca users
Informações sobre o DOI: 10.1080/14740338.2022.2066650 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas